• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)

    5/8/25 4:01:00 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care
    Get the next $PODD alert in real time by email

    Raising Full Year Revenue and Gross Margin Guidance

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025.

    "Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our Podders," said Ashley McEvoy, President and CEO. "I'd like to thank the team and Board of Directors for their incredible support. Insulet is just getting started on an exciting journey to revolutionize diabetes management globally. I am energized and honored to embark on that journey with all of you."

    First Quarter Financial Highlights:

    • Revenue of $569.0 million, up 28.8%, or 29.8% in constant currency, compared with $441.7 million in the prior year, exceeds the high end of the Company's guidance range of 25% in constant currency
      • Total Omnipod revenue of $554.1 million, an increase of 28.0%, or 29.0% in constant currency
        • U.S. Omnipod revenue of $401.7 million, an increase of 26.4%
        • International Omnipod revenue of $152.4 million, an increase of 32.2%, or 36.1% in constant currency
      • Drug Delivery revenue of $14.9 million
    • Gross margin of 71.9%, up 240 basis points, compared with 69.5% in the prior year
    • Operating income of $88.8 million, or 15.6% of revenue, up 270 basis points, compared with $56.9 million, or 12.9% of revenue, in the prior year
    • Adjusted operating income1 of $93.5 million, or 16.4% of revenue, up 350 basis points over prior year
    • Net income of $35.4 million, or $0.50 per diluted share, compared with $51.5 million, or $0.73 per diluted share, in the prior year
    • Adjusted net income1 of $73.7 million, or $1.02 per diluted share
    • Adjusted EBITDA1 of $133.9 million, or 23.5% of revenue, up 330 basis points, compared with $89.2 million, or 20.2% of revenue, in the prior year
    • Operating cash flow of $63.8 million, compared with $87.6 million in the prior year
    • Free cash flow1 of $51.5 million, compared with $65.5 million in the prior year

    Recent Strategic Highlights:

    • Launched Omnipod 5 in Australia, Belgium, Canada, and Switzerland, marking nine new countries where Omnipod 5 has become available since the start of the year and 14 overall globally
    • Presented RADIANT trial data at the Advanced Technologies & Treatments for Diabetes (ATTD) International Conference, which is the first randomized controlled trial to evaluate direct transition from multiple daily injections to automated insulin delivery in adults and children with type 1 diabetes. Compared to people using multiple daily injections with a continuous glucose monitor, Omnipod 5 demonstrated an average reduction in HbA1c of -0.8% and an average of 5.4 hours more per day with glucose levels in the target range without an increase in hypoglycemia2
    • Successfully issued $450 million senior unsecured notes and upsized and extended the maturity of revolving credit facility. Extinguished $420 million principal of convertible notes to date
    • Board of Directors authorized a program to repurchase up to $125 million of common stock through December 31, 2026 to offset dilution from stock-based compensation
    ____________________________

    1 See description of non-GAAP financial measures contained in this release.

    2 RADIANT press release: Link

    2025 Outlook:

    For the quarter ending June 30, 2025 and year ending December 31, 2025, the Company is providing the following guidance (revenue in constant currency):

     

    Q2 2025 Guidance

     

    FY 2025 Guidance

    (as of 5/8/2025)

     

    FY 2025 Prior Guidance

    (as of 2/20/2025)

    U.S. Omnipod

    22% - 25%

     

    18% - 21%

     

    16% - 20%

    International Omnipod

    27% - 30%

     

    27% - 30%

     

    22% - 26%

    Total Omnipod

    23% - 26%

     

    20% - 23%

     

    17% - 21%

    Drug Delivery

    10% - 15%

     

    (35)% - (25)%

     

    (55)% - (45)%

    Total

    23% - 26%

     

    19% - 22%

     

    16% - 20%

     

     

     

     

     

     

    Gross Margin

     

     

    ~71%

     

    ~70.5%

    Adjusted Operating Margin

     

     

    ~16.5%

     

    ~16.5%

     

     

     

     

     

     

    Conference Call:

    Insulet will host a conference call at 4:30 p.m. (Eastern Time) on May 8, 2025 to discuss the financial results and outlook. The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future reference. The live call may also be accessed by dialing (888) 770-7129 for domestic callers or (929) 203-2109 for international callers, passcode 5904836.

    About Insulet Corporation:

    Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit insulet.com or omnipod.com.

    Non-GAAP Measures:

    The Company uses the following non-GAAP financial measures:

    • Constant currency revenue growth, which represents the change in revenue between current and prior year periods using the exchange rate in effect during the applicable prior year period. Insulet presents constant currency revenue growth because management believes it provides meaningful information regarding the Company's results on a consistent and comparable basis. Management uses this non-GAAP financial measure, in addition to financial measures in accordance with generally accepted accounting principles in the United States (GAAP), to evaluate the Company's operating results. It is also one of the performance metrics that determines management incentive compensation.
    • Adjusted gross margin, adjusted gross margin as a percentage of revenue, adjusted operating income, adjusted operating income as a percentage of revenue, adjusted net income, and adjusted diluted earnings per share exclude the impact of certain significant transactions or events, such as legal settlements, medical device corrections, gains (losses) on investments and loss on extinguishment of debt, that affect the period-to-period comparability of the Company's performance, as applicable.
    • Adjusted EBITDA, which represents net income plus net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense and other significant transactions or events, such as legal settlements, medical device corrections, gains (losses) on investments and loss on extinguishment of debt, which affect the period-to-period comparability of the Company's performance, as applicable, and adjusted EBITDA as a percentage of revenue.
    • Free cash flow, which is defined as net cash provided by operating activities less capital expenditures.

    Insulet presents the above non-GAAP financial measures because management uses them as supplemental measures in assessing the Company's performance, and the Company believes they are helpful to investors and other interested parties as measures of comparative performance from period to period. They also are commonly used measures in determining business value, and the Company uses them internally to report results.

    These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company's reported financial results prepared in accordance with GAAP. Furthermore, the Company's definition of these non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, Insulet strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety.

    Forward-Looking Statement:

    This press release contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials, and the approval of products by regulatory bodies. These forward-looking statements are based on management's current beliefs, assumptions and estimates and are not intended to be a guarantee of future events or performance. If management's underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by the forward-looking statements.

    Risks and uncertainties include, but are not limited to our dependence on a principal product platform; the impact of competitive products, technological change and product innovation; our ability to maintain an effective sales force and expand our distribution network; our ability to maintain and grow our customer base; our ability to scale the business to support revenue growth; our ability to secure and retain adequate coverage or reimbursement from third-party payors; the impact of healthcare reform laws; our ability to design, develop, manufacture and commercialize future products; unfavorable results of clinical studies, including issues with third parties conducting any studies, or future publication of articles or announcement of positions by diabetes associations or other organizations that are unfavorable; our ability to protect our intellectual property and other proprietary rights; potential conflicts with the intellectual property of third parties; our inability to maintain or enter into new license or other agreements with respect to continuous glucose monitors, data management systems or other rights necessary to sell our current product and/or commercialize future products; worldwide macroeconomic and geopolitical uncertainty, as well as risks associated with public health crises and pandemics, including government actions and restrictive measures implemented in response, supply chain disruptions, delays in clinical trials, and other impacts to the business, our customers, suppliers, and employees; international regulatory, commercial and logistics business risks, including the implementation of tariffs; the potential violation of anti-bribery/anti-corruption laws; the concentration of manufacturing operations and storage of inventory in a limited number of locations; supply problems or price fluctuations with sole source or third-party suppliers on which we are dependent; failure to retain key suppliers; challenges to the future development of our non-insulin drug delivery product line; our failure or that of our contract manufacturer or component suppliers to comply with the U.S. Food and Drug Administration's quality system regulations or other manufacturing difficulties; extensive government regulation applicable to medical devices, as well as complex and evolving privacy and data protection laws; our use of artificial intelligence tools; adverse regulatory or legal actions relating to current or future Omnipod products; potential adverse impacts resulting from a recall, or discovery of serious safety issues, or product liability lawsuits relating to off-label use; breaches or failures of our product or information technology systems, including by cyberattack; our ability to attract, motivate, and retain key personnel; risks associated with potential future acquisitions or investments in new businesses; ability to raise additional funds on acceptable terms or at all; the volatility of the trading price of our common stock; changes in tax laws or exposure to significant tax liabilities; and risks related to the conversion of outstanding Convertible Senior Notes.

    For a further list and description of these and other important risks and uncertainties that may affect the Company's future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which the Company may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q the Company has filed or will file hereafter. Any forward-looking statement made in this release speaks only as of the date of this release. Insulet does not undertake to update any forward-looking statement, other than as required by law.

    ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.

     

    INSULET CORPORATION

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

     

     

    Three Months Ended March 31,

    (dollars in millions, except per share data)

     

    2025

     

     

     

    2024

     

    Revenue

    $

    569.0

     

     

    $

    441.7

     

    Cost of revenue

     

    160.0

     

     

     

    134.9

     

    Gross profit

     

    409.0

     

     

     

    306.8

     

    Research and development expenses

     

    59.6

     

     

     

    50.2

     

    Selling, general and administrative expenses

     

    260.6

     

     

     

    199.7

     

    Operating income

     

    88.8

     

     

     

    56.9

     

    Interest income (expense), net

     

    1.1

     

     

     

    (1.3

    )

    Loss on extinguishment of debt

     

    (39.5

    )

     

     

    —

     

    Other expense, net

     

    (2.3

    )

     

     

    (0.7

    )

    Income before income taxes

     

    48.1

     

     

     

    54.9

     

    Income tax expense

     

    (12.7

    )

     

     

    (3.4

    )

    Net income

    $

    35.4

     

     

    $

    51.5

     

     

     

     

     

    Earnings per share:

     

     

     

    Basic

    $

    0.50

     

     

    $

    0.74

     

    Diluted

    $

    0.50

     

     

    $

    0.73

     

    Weighted-average number of common shares outstanding (in thousands):

     

     

     

    Basic

     

    70,272

     

     

     

    69,957

     

    Diluted

     

    74,111

     

     

     

    73,741

     

     

    RECONCILIATION OF DILUTED NET INCOME (UNAUDITED)

     

     

    Three Months Ended March 31,

    (in millions)

     

    2025

     

     

    2024

    Net income

    $

    35.4

     

    $

    51.5

    Add back interest expense, net of tax attributable to assumed conversion of convertible senior notes

     

    1.8

     

     

    2.6

    Net income, diluted

    $

    37.2

     

    $

    54.1

     

    INSULET CORPORATION

    CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

     

    (dollars in millions)

    March 31, 2025

     

    December 31, 2024

    ASSETS

     

     

     

    Cash and cash equivalents

    $

    1,283.1

     

    $

    953.4

    Accounts receivable, net

     

    402.3

     

     

    365.5

    Inventories

     

    440.8

     

     

    430.4

    Prepaid expenses and other current assets

     

    202.2

     

     

    142.0

    Total current assets

     

    2,328.4

     

     

    1,891.3

    Property, plant and equipment, net

     

    718.7

     

     

    723.1

    Goodwill and other intangible assets, net

     

    151.3

     

     

    150.0

    Other assets

     

    318.9

     

     

    323.3

    Total assets

    $

    3,517.3

     

    $

    3,087.7

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

    Accounts payable

    $

    57.6

     

    $

    19.8

    Accrued expenses and other current liabilities

     

    379.7

     

     

    424.8

    Current portion of long-term debt

     

    83.1

     

     

    83.8

    Total current liabilities

     

    520.4

     

     

    528.4

    Long-term debt, net

     

    1,612.3

     

     

    1,296.1

    Other liabilities

     

    53.9

     

     

    51.6

    Total liabilities

     

    2,186.6

     

     

    1,876.1

    Stockholders' equity

     

    1,330.7

     

     

    1,211.6

    Total liabilities and stockholders' equity

    $

    3,517.3

     

    $

    3,087.7

     

    INSULET CORPORATION

    NON-GAAP RECONCILIATIONS (UNAUDITED)

     

    CONSTANT CURRENCY REVENUE GROWTH

     

     

    Three Months Ended March 31,

     

     

     

     

     

     

    (dollars in millions)

     

    2025

     

     

    2024

     

    Percent Change

     

    Currency

    Impact

     

    Constant

    Currency

    Revenue:

     

     

     

     

     

     

     

     

     

    U.S. Omnipod

    $

    401.7

     

    $

    317.7

     

    26.4%

     

    —%

     

    26.4%

    International Omnipod

     

    152.4

     

     

    115.3

     

    32.2%

     

    (3.9)%

     

    36.1%

    Total Omnipod

     

    554.1

     

     

    433.0

     

    28.0%

     

    (1.0)%

     

    29.0%

    Drug Delivery

     

    14.9

     

     

    8.7

     

    71.3%

     

    —%

     

    71.3%

    Total

    $

    569.0

     

    $

    441.7

     

    28.8%

     

    (1.0)%

     

    29.8%

     

    ADJUSTED OPERATING INCOME, NET INCOME & DILUTED EPS

     

     

    Three Months Ended March 31, 2025

    (in millions, except per share data)

    Operating

    Income

     

    Income before

    Income Taxes

     

    Net Income(4)

     

    Net Income,

    Diluted

     

    Diluted

    Earnings per

    Share

     

    Effective Tax

    Rates

    GAAP

    $

    88.8

     

    $

    48.1

     

    $

    35.4

     

    $

    37.2

     

    $

    0.50

     

    26.4%

    Loss on investments(1)

     

    4.7

     

     

    7.5

     

     

    5.8

     

     

    5.8

     

    $

    0.08

     

     

    Loss on extinguishment of debt(2)

     

    —

     

     

    39.5

     

     

    39.0

     

     

    39.0

     

    $

    0.53

     

     

    Tax matters(3)

     

    —

     

     

    —

     

     

    (6.5)

     

     

    (6.5)

     

    $

    (0.09)

     

     

    Non-GAAP

    $

    93.5

     

    $

    95.1

     

    $

    73.7

     

    $

    75.5

     

    $

    1.02

     

    22.6%

     

    (1) Represents a provision for credit loss included in selling, general and administrative expenses related to a debt investment and an impairment included in other expense related to an equity investment.

    (2) Relates to the repurchase of a portion of the Company's convertible debt.

    (3) Primarily represents consolidating effective tax rate adjustment related to non-GAAP items and excess tax benefits related to employee share-based compensation.

    (4) The tax effect on non-GAAP adjustments is calculated based on applicable local statutory rates.

     

    INSULET CORPORATION

    NON-GAAP RECONCILIATIONS (UNAUDITED) (CONTINUED)

     

     

    ADJUSTED EBITDA

     

     

    Three Months Ended March 31,

    (dollars in millions)

     

    2025

     

     

    Percent of

    Revenue

     

     

    2024

     

    Percent of

    Revenue

    Net income

    $

    35.4

     

     

    6.2%

     

    $

    51.5

     

    11.7%

    Interest (income) expense, net

     

    (1.1

    )

     

     

     

     

    1.3

     

     

    Income tax expense

     

    12.7

     

     

     

     

     

    3.4

     

     

    Depreciation and amortization

     

    21.7

     

     

     

     

     

    18.8

     

     

    Stock-based compensation expense

     

    18.2

     

     

     

     

     

    14.2

     

     

    Loss on extinguishment of debt(1)

     

    39.5

     

     

     

     

     

    —

     

     

    Loss on investments(2)

     

    7.5

     

     

     

     

     

    —

     

     

    Adjusted EBITDA

    $

    133.9

     

     

    23.5%

     

    $

    89.2

     

    20.2%

     

    (1) Relates to the repurchase of a portion of the Company's convertible debt.

    (2) Represents a provision for credit loss related to a debt investment and an impairment related to an equity investment.

    FREE CASH FLOW

     

     

    Three Months Ended March 31,

    (dollars in millions)

     

    2025

     

     

     

    2024

     

    Net cash provided by operating activities

    $

    63.8

     

     

    $

    87.6

     

    Capital expenditures

     

    (12.3

    )

     

     

    (22.1

    )

    Free cash flow

    $

    51.5

     

     

    $

    65.5

     

     

    INSULET CORPORATION

    NON-GAAP RECONCILIATIONS (UNAUDITED) CONTINUED

    REVENUE GUIDANCE

     

     

    Year Ending December 31, 2025

     

    Revenue Growth

    GAAP

     

    Currency

    Impact

     

    Constant

    Currency

    U.S. Omnipod

    18% - 21%

     

    —%

     

    18% - 21%

    International Omnipod

    29% - 32%

     

    2%

     

    27% - 30%

    Total Omnipod

    21% - 24%

     

    1%

     

    20% - 23%

    Drug Delivery

    (35)% - (25)%

     

    —%

     

    (35)% - (25)%

    Total

    20% - 23%

     

    1%

     

    19% - 22%

     

    Three Months Ended June 30, 2025

     

    Revenue Growth

    GAAP

     

    Currency

    Impact

     

    Constant

    Currency

    U.S. Omnipod

    22% - 25%

     

    —%

     

    22% - 25%

    International Omnipod

    32% - 35%

     

    5%

     

    27% - 30%

    Total Omnipod

    24% - 27%

     

    1%

     

    23% - 26%

    Drug Delivery

    10% - 15%

     

    —%

     

    10% - 15%

    Total

    24% - 27%

     

    1%

     

    23% - 26%

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250508351395/en/

    Investor Relations:

    June Lazaroff

    Senior Director, Investor Relations

    (978) 600-7718

    [email protected]

    Media:

    Angela Geryak Wiczek

    Senior Director, Corporate Communications

    (978) 932-0611

    [email protected]

    Get the next $PODD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PODD

    DatePrice TargetRatingAnalyst
    4/29/2025Outperform → Peer Perform
    Wolfe Research
    3/6/2025$340.00Outperform
    RBC Capital Mkts
    11/6/2024$300.00Outperform
    Bernstein
    5/30/2024$235.00Buy
    Redburn Atlantic
    5/7/2024$200.00Peer Perform → Outperform
    Wolfe Research
    12/21/2023$180.00 → $238.00Neutral → Outperform
    Robert W. Baird
    12/4/2023$185.00 → $234.00Equal-Weight → Overweight
    Morgan Stanley
    10/2/2023$260.00 → $240.00Hold → Buy
    Jefferies
    More analyst ratings

    $PODD
    Financials

    Live finance-specific insights

    See more
    • Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)

      Raising Full Year Revenue and Gross Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. "Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our P

      5/8/25 4:01:00 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2025 on May 8, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-210

      4/3/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year

      Represents 9th Consecutive Year of 20% or More Constant Currency1 Revenue Growth; Annual Revenue Surpasses $2 Billion Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2024. "We concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business, and exceeding our growth and margin objectives," said Jim Hollingshead, Insulet President and Chief Executive Officer. "We continue to see robust demand and momentum for Omnipod 5, now available to both type 1 an

      2/20/25 4:01:00 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      8/29/24 4:17:26 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Singh Prem bought $169 worth of shares (1 units at $168.92), increasing direct ownership by 0.02% to 4,032 units

      4 - INSULET CORP (0001145197) (Issuer)

      9/21/23 4:48:23 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & Treasurer Chadwick Ana Maria covered exercise/tax liability with 1,765 shares, decreasing direct ownership by 11% to 14,263 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      5/5/25 4:53:31 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • New insider Mcevoy Ashley claimed ownership of 4 shares (SEC Form 3)

      3 - INSULET CORP (0001145197) (Issuer)

      5/2/25 4:19:13 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Former President and CEO Hollingshead James covered exercise/tax liability with 3,587 shares, decreasing direct ownership by 6% to 61,247 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      4/30/25 4:25:11 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PODD
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $PODD
    SEC Filings

    See more

    $PODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $PODD
    Leadership Updates

    Live Leadership Updates

    See more
    • Insulet downgraded by Wolfe Research

      Wolfe Research downgraded Insulet from Outperform to Peer Perform

      4/29/25 8:07:24 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • RBC Capital Mkts initiated coverage on Insulet with a new price target

      RBC Capital Mkts initiated coverage of Insulet with a rating of Outperform and set a new price target of $340.00

      3/6/25 7:30:36 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Bernstein initiated coverage on Insulet with a new price target

      Bernstein initiated coverage of Insulet with a rating of Outperform and set a new price target of $300.00

      11/6/24 6:20:05 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)

      Raising Full Year Revenue and Gross Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. "Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our P

      5/8/25 4:01:00 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Appoints Ashley McEvoy President and CEO

      Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the rig

      4/28/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Launches Omnipod® 5 Automated Insulin Delivery System in Canada, a Revolutionary New Technology for People Living with Type 1 Diabetes Ages Two Years and Above

      New Diabetes Canada Guidelines1 recommend people with type 1 diabetes use an Automated Insulin Delivery System (AID) System for diabetes managementApproximately 300,000 Canadians have type 1 diabetes, with the number of cases growing at an estimated 4.4% per year2The Omnipod 5 System is designed to be customer-centric and aims to deliver exceptional ease of use. It has demonstrated strong clinical results including lower A1c and improved time in range, while maintaining low time in hypoglycemia3OAKVILLE, ON, April 7, 2025 /CNW/ - Insulet Corporation (NASDAQ:PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Omnipod 5 is now

      4/7/25 7:07:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - INSULET CORP (0001145197) (Filer)

      5/8/25 4:02:51 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Insulet Corporation

      DEF 14A - INSULET CORP (0001145197) (Filer)

      4/29/25 4:05:45 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Corporation filed SEC Form 8-K: Leadership Update

      8-K - INSULET CORP (0001145197) (Filer)

      4/28/25 4:13:09 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Insulet Corporation

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      11/12/24 12:53:28 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Insulet Corporation

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      10/7/24 11:37:08 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Insulet Corporation (Amendment)

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      2/13/24 5:06:23 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Appoints Ashley McEvoy President and CEO

      Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the rig

      4/28/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet to Host Investor Day on June 5, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's leading Omnipod® 5 platform, strategic priorities, market opportunities, growth drivers, innovation roadmap, and financial outlook. Presentations will begin at 10:00 a.m. (ET) and conclude at approximately 1:30 p.m. (ET). The Company

      3/11/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances